No title
Acute myeloid leukemia (AML) is the most common leukemia in adults and is coupled to a poor prognosis, with a five-year overall survival of around 20% and a high risk of relapse. In AML, immature myeloid cells accumulate rapidly in the bone marrow impairing normal blood cell development. Current treatments fail to eradicate the leukemia stem cells, which is a self-renewing population of leukemia c
